PUBLISHER: The Business Research Company | PRODUCT CODE: 1946718
PUBLISHER: The Business Research Company | PRODUCT CODE: 1946718
Particle therapy is an advanced cancer treatment that employs charged particles, such as protons or heavier ions, to administer radiation therapy directly to cancerous tumors. This method primarily targets energetic ionizing particles at the tumor location, aiming to improve treatment outcomes for patients with various types of tumors, particularly those that are difficult to treat using conventional radiation therapy.
Two primary types of therapies fall under the umbrella of particle therapy, proton therapy and heavy ion therapy. Proton therapy is a specialized form of radiation therapy employed in cancer treatment. It encompasses both single-room systems and multi-room systems, providing versatility in its application. Proton therapy is utilized for the treatment of various cancers, including but not limited to pediatric cancer, prostate cancer, lung cancer, breast cancer, and cancers affecting the brain and spinal cord. The primary end users of particle therapy are hospitals, academic institutions, and research centers. Particle therapy offers a targeted and precise approach to cancer treatment, minimizing damage to surrounding healthy tissues and enhancing the therapeutic effectiveness of radiation.
Tariffs are impacting the particle therapy market by increasing costs of imported accelerators, beam delivery systems, superconducting magnets, imaging components, and control electronics required for proton and heavy ion therapy systems. North America and Europe are most affected due to reliance on specialized imported equipment, while Asia-Pacific faces higher capital costs for new installations. These tariffs are raising upfront investment requirements and extending project timelines for new therapy centers. However, they are also encouraging local manufacturing partnerships, regional assembly capabilities, and long-term innovation in cost-efficient particle therapy system design.
The particle therapy market research report is one of a series of new reports from The Business Research Company that provides particle therapy market statistics, including particle therapy industry global market size, regional shares, competitors with a particle therapy market share, detailed particle therapy market segments, market trends and opportunities, and any further data you may need to thrive in the particle therapy industry. This particle therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The particle therapy market size has grown rapidly in recent years. It will grow from $1.36 billion in 2025 to $1.53 billion in 2026 at a compound annual growth rate (CAGR) of 12.1%. The growth in the historic period can be attributed to rising cancer incidence rates, early adoption of proton therapy technologies, expansion of specialized oncology centers, increasing clinical evidence supporting particle therapy, investments by academic research hospitals.
The particle therapy market size is expected to see rapid growth in the next few years. It will grow to $2.44 billion in 2030 at a compound annual growth rate (CAGR) of 12.4%. The growth in the forecast period can be attributed to expansion of personalized cancer treatment approaches, increasing healthcare spending on advanced oncology care, growing demand for precision radiation therapies, technological advancements in accelerator systems, rising adoption in emerging healthcare markets. Major trends in the forecast period include increasing adoption of pencil beam scanning systems, rising deployment of single-room particle therapy centers, growing use of carbon ion therapy, expansion of precision treatment planning capabilities, enhanced focus on pediatric oncology applications.
The increasing prevalence of cancer is anticipated to drive the growth of the particle therapy market in the future. Cancer is a complex and varied group of diseases marked by the abnormal growth and multiplication of cells in the body. Particle therapy effectively treats cancer through precise radiation delivery, utilizing positively charged particles (protons) that are accelerated to high speeds and focused on the tumor. For instance, in April 2024, the International Agency for Research on Cancer (IARC), a France-based intergovernmental agency, reported that nearly 20 million new cancer cases were recorded in 2022, resulting in almost 10 million deaths. Projections based on demographic trends indicate that the annual incidence of new cancer cases could reach 35 million by 2050, representing a 77% increase from the 2022 figures. Therefore, the rising prevalence of cancer is a key factor driving the growth of the particle therapy market.
Key companies in the particle therapy market are intensifying their efforts to develop innovative therapies, with a particular focus on proton therapy solutions, to gain a competitive advantage. Proton therapy technology, a sophisticated form of cancer treatment utilizing protons and positively charged particles, delivers precise and targeted radiation to cancer cells. For instance, in April 2023, P-Cure, an Israel-based high-med-tech company, obtained clearance from the United States Food and Drug Administration (USFDA) for its Adaptive Proton Therapy Solution, allowing sales in the USA. This affordable proton therapy technology is designed for targeted cancer treatment with significantly reduced treatment-related side effects. P-Cure's innovative upright solution, the world's first FDA-approved methodology for patient positioning, enables seated treatment, enhancing both patient comfort and clinical outcomes.
In February 2025, Ion Beam Applications S.A. (IBA), a Belgium-based provider of particle accelerator technology and proton therapy solutions, partnered with the Asian Institute of Gastroenterology (AIG) to enhance cancer care in South Asia through advanced proton therapy. Under the partnership, IBA will supply its ProteusONE compact proton therapy system to the new Oncology Centre at AIG Hospitals' Gachibowli campus in Hyderabad, India, supporting the expansion of state-of-the-art proton therapy capabilities in the region. AIG Hospitals is an India-based healthcare institution specializing in gastroenterology and comprehensive cancer care services.
Major companies operating in the particle therapy market are Hitachi Ltd., Mitsubishi Electric Corporation, Sumitomo Heavy Industries Ltd., Varian Medical Systems Inc., IBA Worldwide, Mevion Medical Systems Inc., ProNova Solutions LLC, Advanced Oncotherapy plc, Shinva Medical Instrument Co. Ltd., Optivus Proton Therapy Inc., Protom International Inc., Danfysik AS, Toshiba Energy Systems And Solutions Corporation, Canon Medical Systems Corporation, Siemens Healthineers AG, Koninklijke Philips N.V., GE Healthcare, Elekta AB, Accuray Incorporated, Xstrahl Inc.
North America was the largest region in the particle therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the particle therapy market report during the forecast period. The regions covered in the particle therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the particle therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The particle therapy market includes of revenues earned by entities by providing particle therapy services such as treatment planning, particle beam delivery, imaging and simulation, treatment sessions, patient monitoring, and support services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Particle Therapy Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses particle therapy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for particle therapy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The particle therapy market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.